DATROWAY® Plus Rilvegostomig Demonstrates Encouraging Tumor Responses in Metastatic Urothelial Cancer Patients in TROPION-PanTumor03 Phase 2 Study

Efficacy of DATROWAY: The combination of DATROWAY and rilvegostomig showed a confirmed objective response rate of 68.2% and a disease control rate of 95.5% in previously untreated, cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer, as presented at the ESMO Congress.

Ongoing Trials: Daiichi Sankyo has initiated the TROPION-Urothelial03 phase 2/3 trial to further evaluate DATROWAY combined with platinum-based chemotherapy in patients with metastatic urothelial cancer who have progressed after prior treatments.

Safety Profile: The safety profile of DATROWAY plus rilvegostomig was consistent with known profiles, with grade 3 or higher treatment-related adverse events observed in 18.2% of first-line and 38.9% of second-line patients, including increased amylase and neutropenia.

Need for New Treatments: Experts emphasize the urgent need for new therapeutic options in metastatic urothelial cancer, as current treatments often lead to disease progression, highlighting the potential of DATROWAY in improving patient outcomes.